loader2
Login Open ICICI 3-in-1 Account

STRIDES PHARMA RECEIVES USFDA APPROVAL FOR URSODIOL CAPSULES

Published on Jan 25, 2021 13:31

Strides Pharma Science announced that its step-down wholly owned subsidiary, Strides Pharma Global, Singapore, has received approval for Ursodiol Capsules USP, 300 mg from the United States Food & Drug Administration (USFDA). The product is bioequivalent and therapeutically equivalent to the Reference Listed Drug (RLD), Actigall? Capsules, 300 mg, of Allergan Sales, LLC.

According to IQVIA MAT November 2020 data, the US market for Ursodiol Capsules USP, 300 mg is approximately US$ 45 Mn. The product will be manufactured at the company`s facility at Bengaluru and will be marketed by Strides Pharma Inc. in the US market.

The company has 127 cumulative ANDA filings with USFDA of which 96 ANDAs have been approved and 31 are pending approval

Powered by Capital Market - Live News